Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Equivalence Clinical Trial to Investigate the Efficacy and Safety of a Single Injection of 100 microg Org 36286 (Corifollitropin Alfa) to Induce Multifollicular Development for Ovarian Stimulation Using Daily Recombinant FSH as Reference

Trial Profile

A Phase III, Equivalence Clinical Trial to Investigate the Efficacy and Safety of a Single Injection of 100 microg Org 36286 (Corifollitropin Alfa) to Induce Multifollicular Development for Ovarian Stimulation Using Daily Recombinant FSH as Reference

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2018

At a glance

  • Drugs Corifollitropin alfa; Follitropin beta; Progesterone; Progesterone
  • Indications Female infertility
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ENSURE
  • Sponsors Organon; Schering-Plough
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 03 Jul 2012 Additional location (Denmark) added as reported by European Clinical Trials Database.(Parent trial: EudraCT2006-003811-36).
    • 01 Jul 2009 Results have been presented at the European Society of Human Reproduction and Embryology, according to a Schering-Plough media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top